Poorval Joshi

Poorval Joshi

Auto-generated profile, based on publicly available information

Poorval Joshi

Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PJPoorval M. Joshi
Poorval M. Joshi
SSShari L. Sutor
Shari L. Sutor
CHCatherine J. Huntoon
Catherine J. Huntoon
LKLarry M. Karnitz
Larry M. Karnitz
Mutations in the tumor suppressors BRCA1 and BRCA2, which encode proteins that are key participants in homologous recombination (HR) repair, occur in ∼20% of high grade serous ovarian cancers. Although only 20% of these tumors have mutations in BRCA1 and BRCA2, nearly 50% of these tumors have defects in HR. Notably, however, the underlying genetic defects that give rise to HR defects in the absence of BRCA1 and BRCA2 mutations have not been fully elucidated. Here we show that the recurrent somatic CDK12 mutations identified in ovarian cancers impair the catalytic activity of this kinase, which is involved in the transcription of a subset of genes, including BRCA1 and other DNA repair genes. Furthermore, we show that disabling CDK12 function in ovarian cancer cells reduces BRCA1 levels, disrupts HR repair, and sensitizes these cells to the cross-linking agents melphalan and cisplatin and to the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888). Taken together, these findings suggest that many CDK12 mutations are an unrecognized cause of HR defects in ovarian cancers.

1 June 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
YLYang Liang
Yang Liang
TTToma Tebaldi
Toma Tebaldi
KRKai Rejeski
Kai Rejeski
PJPoorval Joshi
Poorval Joshi
GSGiovanni Stefani
Giovanni Stefani
SHStephanie Halene
Stephanie Halene

1 January 2016 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
AHAmelia M. Huehls
Amelia M. Huehls
CHCatherine J. Huntoon
Catherine J. Huntoon
PJPoorval M. Joshi
Poorval M. Joshi
CBCarly Baehr
Carly Baehr
JWJill M. Wagner
Jill M. Wagner
LKLarry M. Karnitz
Larry M. Karnitz
5-Fluorouracil (5-FU) and its metabolite 5-fluorodeoxyuridine (FdUrd, floxuridine) are chemotherapy agents that are converted to 5-fluorodeoxyuridine monophosphate (FdUMP) and 5-fluorodeoxyuridine triphosphate (FdUTP). FdUMP inhibits thymidylate synthase and causes the accumulation of uracil in the genome, whereas FdUTP is incorporated by DNA polymerases as 5-FU in the genome; however, it remains unclear how either genomically incorporated U or 5-FU contributes to killing. We show that depletion of the uracil DNA glycosylase (UNG) sensitizes tumor cells to FdUrd. Furthermore, we show that UNG depletion does not sensitize cells to the thymidylate synthase inhibitor (raltitrexed), which induces uracil but not 5-FU accumulation, thus indicating that genomically incorporated 5-FU plays a major role in the antineoplastic effects of FdUrd. We also show that 5-FU metabolites do not block the first round of DNA synthesis but instead arrest cells at the G1/S border when cells again attempt replication and activate homologous recombination (HR). This arrest is not due to 5-FU lesions blocking DNA polymerase δ but instead depends, in part, on the thymine DNA glycosylase. Consistent with the activation of HR repair, disruption of HR sensitized cells to FdUrd, especially when UNG was disabled. These results show that 5-FU lesions that escape UNG repair activate HR, which promotes cell survival.

4 May 2017 in Blood
Verified
Journal Article
Closed access
PDF file
PJPoorval Joshi
Poorval Joshi
SHStephanie Halene
Stephanie Halene
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Mutations in RNA splicing factors are the single most common class of genetic alterations in myelodysplastic syndrome (MDS) patients. Although much has been learned about how these mutations affect splicing at a global- and transcript-specific level, critical questions about the role of these mutations in MDS development and maintenance remain. Here we present the questions to be addressed in order to understand the unique enrichment of these mutations in MDS.

1 March 2017 in Journal of Virological Methods
Verified
Journal Article
Closed access
LELyns Etienne
Lyns Etienne
PJPoorval Joshi
Poorval Joshi
LDLaura Dingle
Laura Dingle
EHEugene Huang
Eugene Huang
PGPeter Grzesik
Peter Grzesik
PDPrashant Desai
Prashant Desai

1 May 2017 in Virus Research
Verified
Journal Article
Closed access
PGPeter Grzesik
Peter Grzesik
DMDerek MacMath
Derek MacMath
BHBrandon Henson
Brandon Henson
SPSanjana Prasad
Sanjana Prasad
PJPoorval Joshi
Poorval Joshi
PDPrashant Desai
Prashant Desai